Market Intelligence, Clinical Progress, and High-Purity Reagents for Pancreatic Cancer and Solid Tumor Targeted Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PLEC drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PLEC Recombinant Protein (Targeting Domain) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for binding assays. |
View PLEC Products |
| Gene Delivery | PLEC Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and surface expression validation. |
View PLEC Products |
| Benchmark Ab | Anti-PLEC Recombinant Antibody High-affinity positive control for FACS, IHC, and internalization assays. |
View PLEC Products |
| Validator | PLEC siRNA Set Target-specific knockdown verification in tumor cell lines. |
View PLEC Products |
| Related Target A | ITGB4 (Integrin beta-4) Primary hemidesmosome partner co-localized with Plectin; critical in cell migration and invasion. |
View ITGB4 Products |
| Related Target B | KRAS Driver oncogene in pancreatic ductal adenocarcinoma (PDAC) where surface Plectin translocation is prominent. |
View KRAS Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Surface-Plectin Specificity Screening | Recombinant PLEC fragment proteins strictly sequence-verified for tumor-associated isoform 1. |
| Conformational Cell-Based Assays | Lentivirus for stable overexpression in target cell lines to preserve native membrane-associated conformation. |
| Lack of Controls | Clinical-grade benchmark antibodies included for assay standardization. |
| False Positives | Sequence-specific siRNA sets included for target-knockdown validation. |
Live PLEC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Plectin (PLEC) therapeutics is intensifying, with major players shifting focus from traditional intracellular targets to tumor-specific cell-surface Plectin-1 (tPlectin). As first-generation targeted peptides and peptide-drug conjugates (PDCs) reach the clinic, the next wave of R&D is targeting cell-surface Plectin for antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) therapies, particularly in pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide-Drug Conjugates (PDC) | Preclinical / Academic Consortia | Pancreatic Cancer (PDAC), Ovarian Cancer | Internalization Assay (Need high-purity recombinant PLEC fragments) |
| Antibody-Drug Conjugates (ADC) | Biotech Startups | Solid Tumors, Head & Neck Cancer | Specificity Validation (Need cell-line validation via Lentiviral expression) |
| Targeted Imaging Agents | Clinical Stage Developers | Intraoperative Imaging, Diagnostics | High-affinity binding assays (Need sequence-verified PLEC proteins) |